This paper tackles several statistical controversies that are commonly faced when reporting a major clinical trial. Topics covered include: multiplicity of data, interpreting secondary endpoints and composite endpoints, the value of covariate adjustment, the traumas of subgroup analysis, assessing individual benefits and risks, alternatives to analysis by intention to treat, interpreting surprise findings (good and bad), and the overall quality of clinical trial reports. All is put in 
L ast week's review paper covered the fundamentals of statistical analysis and reporting of randomized clinical trials (RCTs). We now extend those ideas to discuss several controversial statistical issues that are commonly faced in the presentation and interpretation of trial findings.
We explore the problems faced by investigators due to the multiplicity of data available from any RCT, especially regarding multiple endpoints and subgroup analyses. Interpreting composite endpoints is a particular challenge. There is an inconsistency regarding the use of covariate-adjusted analyses.
There is a need for more trials to assess how their overall findings can be translated into assessment of an individual patient's absolute benefits and absolute risks. The merit of analysis by intention to treat (ITT) is considered alongside other options, such as ontreatment analysis. One rarely discussed topic is how to interpret surprisingly large treatment effects (both good and bad) in new trials, which are often quite small in scale.
All of these controversies are summarized in the Central Illustration and are illustrated by topical examples from cardiology trials. The overall aim in clarifying these issues is to enhance the quality of clinical trial reports in medical journals. The same principles apply to conference presentations and sponsor press releases, which are even more prone to distortive reporting.
MULTIPLICITY OF DATA
The key challenge in any report of a major RCT is how to provide a balanced account of the trial's findings,
given the large number of variables collected at baseline and during follow-up, commonly called a "multiplicity of data" (1) . So, out of the potential chaos of the innumerable tables and figures that could be produced for purposes of treatment comparison, how do we validly select what to include in the finite confines of a trial publication in a major journal? Especially, how do we ensure that such a condensed trial report is fair in what it includes; that is, how do we resist the temptation to "play up the positive" by devoting more space in the results and conclusions sections to those findings that put the new treatment in a good light?
A first step to overcome this is to have a predefined statistical analysis plan (SAP) that is fully signed off before database locking and study unblinding. This SAP is prepared by trial statisticians and approved by the trial executive, all of whom must be blind to any interim results by treatment group. A good SAP will not only document exactly which analyses are to be done, but will also elucidate relevant priorities in their interpretation, especially regarding the primary hypothesis, secondary hypotheses, any pre-defined safety concerns, and a potential plethora of exploratory analyses (e.g., subgroup analyses), which are more hypothesisgenerating in spirit.
A particular focus is on the pre-defined primary endpoint, with clear definition of the endpoint itself, the time of follow-up included (either a fixed period [e.g., 90 days], or a fixed calendar date for follow-up of all patients), and the precise statistical method for determining its point estimate, confidence interval (CI), and p value. For time-to-event outcomes this is commonly a hazard ratio (HR) (and 95% CI) with logrank p value, but sometimes a covariate-adjusted analysis is primary (see later discussion on this).
It is good practice to have a pre-defined and limited set of secondary endpoints for treatment efficacy.
Their results are shown alongside those of the primary endpoint; for example, as in Table 1 In this instance, the interpretation appears to be straightforward because the primary endpoint achieved statistical significance for each ticagrelor dose versus placebo and all secondary efficacy endpoints showed trends in the same direction, except for no difference in all-cause death for the higher ticagrelor dose. However, excesses of major bleeding and dyspnea on ticagrelor mean that such efficacy is offset by safety concerns. 
biological explanation as to why the drugs might differ in this respect. Furthermore, a statistical test of heterogeneity comparing the 3 trials' HRs for heart failure is not statistically significant (interaction p ¼ 0.16), and the combined HR is 1.13 (p ¼ 0.04) and 1.12 (p ¼ 0.18) for fixed and random-effect meta-analyses, respectively ( Figure 1 ). This analysis partly hinges on the concept that similar effects should be expected A second important point raised by SYNTAX is that in such strategy trials, the key treatment differences may well be revealed with longer-term follow-up. At 5 years, there is a highly significant excess of MIs in the DES group, and this drives the composite of death, MI, and stroke also to be in favor of CABG. This added credibility to the idea of a survival benefit for candesartan, especially given that the covariateadjusted HR for CV death was 0.87 (95% CI: 0.78 to 0.96; p ¼ 0.006).
In general, we believe that a well-defined appropriate covariate-adjusted analysis is well worth doing in major RCTs. After all, it offers a slight gain in statistical power at no extra cost and with minimal statistical effort, so why miss out on such an opportunity?
The following principles should be followed: 
SUBGROUP ANALYSIS
Patients recruited in a major trial are not a homogeneous bunch: their medical history, demographics, and other baseline features will vary. Hence, it is legitimate to undertake subgroup analyses to see whether the overall result of the trial appears to apply to all eligible patients, or whether there is evidence that real treatment effects depend on certain baseline characteristics.
Of all multiplicity problems in reporting RCTs, interpretation of subgroup analyses presents a particular challenge (19) . First, trials usually lack power to reliably detect subgroup effects. Second, there are many possible subgroups that could be explored, and one needs to guard against data dredging, eliciting false subgroup claims. Third, statistical significance (or not) in a specific subgroup is not a sound basis for making (or ruling out) any subgroup claims; instead, one needs statistical tests of interaction to directly infer whether the treatment effect appears to differ across subgroups.
We explore these ideas in a few examples. When the overall result of a major RCT is neutral, it is tempting to search across subgroups to see if Hazard Ratio (95% CI)
P value for interaction
Hazard ratio (95% 
Primary End Point Death from Cardiovascular Causes
Hazard ratios for the primary endpoint (death from cardiovascular causes or first hospitalization for heart failure) and for death from cardiovascular causes among patients in pre-specified subgroups. The size of the square corresponds to the number of patients in each subgroup. where an interaction is anticipated to exist.
ASSESSING INDIVIDUAL BENEFITS AND RISKS
In most RCT reports, the focus is on the overall relative efficacy and relative safety of the treatments being compared. But even in the absence of any subgroup differences on a relative scale (e.g., on the basis of HRs or odds ratios), there may well be important differences between individuals as regards absolute treatment benefits (26).
For instance, in the EMPHASIS-HF trial (12) of eplerenone versus placebo in heart failure, patients with mild symptoms, the composite primary endpoint, CV death, and heart failure hospitalization, showed a marked benefit over a median 21-month follow-up (HR: 0.63; 95% CI: 0.54 to 0.74; p < 0.0001). There were no apparent subgroup effects on a hazard ratio scale. In a subsequent analysis, each patient was then classified into low-, medium-, and high-risk groups on the basis of a multivariable risk score using 10 commonly-recognized prognostic features (27) . Table 4 shows the consequent treatment benefits by risk group, on both relative and absolute scales. As anticipated, the HR was similar in all risk groups. But, the absolute benefits varied markedly by an absolute scale, how the tradeoff between treatment differences in ischemic efficacy and bleeding harm is patient-specific. For instance, the bleeding risk is of greater concern in elderly women, whereas in a younger man with known CV risk factors, avoidance of future ischemic events is paramount.
Clopidogrel is the drug of choice for the former, whereas prasugrel is a better choice for the latter. *Rate per 100 person-years; primary endpoint is the composite of CV death and heart failure hospitalization. Event rates, HRs, and rate differences for the primary endpoint (CV death and hospitalization for heart failure) by risk group in the EMPHASIS-HF trial. Data from Collier et al. (27) .
Abbreviations as in Tables 1 and 3 .
Pocock et al. compatible with an early increase in risk that persists
Statistical Controversies: Part 2 1 year after stopping treatment ( Figure 3B ). Rofecoxib was withdrawn from worldwide markets due to these safety concerns, although it is worth noting that the second report (38) was published over 3 years after this withdrawal. 
